Uploaded February 2026 | Updated September 2026, 1 week ago
Two founders are racing to solve aging from completely different directions, one by freezing organs to pause time, the other by reprogramming cells to reverse it.
On this episode of Builders, hosts Josh Coyne and Leigh Marie Braswell sit down with Laura Deming (Until) and Jacob Kimmel (NewLimit) to get into the real science behind cryo-preservation and epigenetic reprogramming and how AI is changing the speed at which both are moving.
"If you could just pause time when you had a terminal illness and turn it back on when the cure was there, that'd be amazing." - Laura Deming (Until)
"I made these old cells look young and it worked every time. I couldn't get the idea out of my head." - Jacob Kimmel (NewLimit)
Highlights from the discussion:
- How Until is scaling frozen organ technology from rat kidneys to human-scale organs.
- Why NewLimit's first anti-aging medicine could enter human trials soon.
- The role AI is playing in doubling the rate of longevity drug discovery.
Guests: Laura Deming, CEO at Until, and Jacob Kimmel, Co-founder & President at NewLimit
Connect with us here:
Jacob Kimmel:
X: https://x.com/jacobkimmel?lang=en
LinkedIn: linkedin.com/in/jacob-kimmel
Laura Deming:
X: https://x.com/LauraDeming
LinkedIn: linkedin.com/in/laura-deming-b255362a
Leigh Marie Braswell:
X: https://x.com/LM_Braswell
LinkedIn: linkedin.com/in/leigh-marie-braswell
Josh Coyne:
X: @josh_coyne
LinkedIn: linkedin.com/in/joshuacoyne
Learn more about Kleiner Perkins: kleinerperkins.com
00:00 Trailer
01:03 Introduction
06:51 How It Works: Epigenetics + Vitrification
11:13 Roadmaps, Hiring, and Scaling Science
23:57 Virtual Cell Roadmap (Why Experiments Don’t Scale)
31:16 Reversing Eroom’s Law: AI Cutting Drug Costs + Faster Trials
35:46 What’s Next: Energy, Gene Editing, Sleep + Longevity Habits
Two founders are racing to solve aging from completely different directions, one by freezing organs to pause time, the other by reprogramming cells to reverse it.
On this episode of Builders, hosts Josh Coyne and Leigh Marie Braswell sit down with Laura Deming (Until) and Jacob Kimmel (NewLimit) to get into the real science behind cryo-preservation and epigenetic reprogramming and how AI is changing the speed at which both are moving.
"If you could just pause time when you had a terminal illness and turn it back on when the cure was there, that'd be amazing." - Laura Deming (Until)
"I made these old cells look young and it worked every time. I couldn't get the idea out of my head." - Jacob Kimmel (NewLimit)
Highlights from the discussion:
- How Until is scaling frozen organ technology from rat kidneys to human-scale organs.
- Why NewLimit's first anti-aging medicine could enter human trials soon.
- The role AI is playing in doubling the rate of longevity drug discovery.
Guests: Laura Deming, CEO at Until, and Jacob Kimmel, Co-founder & President at NewLimit
Connect with us here:
Jacob Kimmel:
X: https://x.com/jacobkimmel?lang=en
LinkedIn: linkedin.com/in/jacob-kimmel
Laura Deming:
X: https://x.com/LauraDeming
LinkedIn: linkedin.com/in/laura-deming-b255362a
Leigh Marie Braswell:
X: https://x.com/LM_Braswell
LinkedIn: linkedin.com/in/leigh-marie-braswell
Josh Coyne:
X: @josh_coyne
LinkedIn: linkedin.com/in/joshuacoyne
Learn more about Kleiner Perkins: kleinerperkins.com
00:00 Trailer
01:03 Introduction
06:51 How It Works: Epigenetics + Vitrification
11:13 Roadmaps, Hiring, and Scaling Science
23:57 Virtual Cell Roadmap (Why Experiments Don’t Scale)
31:16 Reversing Eroom’s Law: AI Cutting Drug Costs + Faster Trials
35:46 What’s Next: Energy, Gene Editing, Sleep + Longevity Habits
